- Investing.com
Symbol | Exchange | Currency | |||
---|---|---|---|---|---|
AZN | · | NASDAQ | · | USD | |
AZNl | · | BATS Europe | · | GBP | |
AZNs | · | BATS Europe | · | SEK | |
AZNCF | · | OTC Markets | · | USD | |
3SAZ | · | London | · | GBP | |
AZN | · | London | · | GBP | |
3LAZ | · | London | · | GBP | |
AZNN | · | BIVA | · | MXN | |
AZNN | · | Mexico | · | MXN | |
AZN | · | Stockholm | · | SEK | |
AZN | · | TradeGate | · | EUR | |
AZN | · | Xetra | · | EUR | |
AZNPy | · | Frankfurt | · | EUR | |
AZN | · | Frankfurt | · | EUR | |
AZNPy | · | TradeGate | · | EUR | |
AZNm | · | Buenos Aires | · | ARS | |
A1ZN34 | · | B3 | · | BRL | |
AZNA | · | Vienna | · | EUR |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Oncology Powerhouse | AstraZeneca's strong oncology portfolio drives growth, with flagship drugs like Imfinzi showing impressive revenue increases despite market challenges |
Pipeline Potential | Explore AstraZeneca's diverse pipeline, including promising treatments in hematologic malignancies and the highly anticipated AVANZAR trial results |
Strategic Growth | Delve into AstraZeneca's strategic acquisitions and partnerships, enhancing its portfolio and pipeline across multiple therapeutic areas |
Market Outlook | Analysts project positive growth, with price targets ranging from $85 to $89, reflecting confidence in AstraZeneca's financial health and market position |
Metrics to compare | AZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZNPeersSector | |
---|---|---|---|---|
P/E Ratio | 29.7x | 18.7x | −0.4x | |
PEG Ratio | 1.31 | 0.09 | 0.00 | |
Price/Book | 5.6x | 3.1x | 2.6x | |
Price / LTM Sales | 4.2x | 2.2x | 3.1x | |
Upside (Analyst Target) | 10.9% | 4.1% | 51.1% | |
Fair Value Upside | Unlock | 31.9% | 8.9% | Unlock |